OKYO Pharma (OKYO) announces the filing of its application for Fast Track designation, FTD, with the U.S. Food and Drug Administration, FDA, for urcosimod for the treatment of neuropathic corneal pain, which is a debilitating condition affecting many tens of thousands worldwide, and is characterized by chronic, severe eye discomfort for which there is no FDA-approved, effective treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKYO:
- Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential
- OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod
- Okyo Pharma announces OK-101 officially assigned USAN, urcosimod
- Yi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory Challenges
- OKYO Pharma Executives Increase Shareholdings, Affirming Market Confidence